BioPharma Resources

Drug Trial Radar · NCT06094010

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

A Phase IIIb Multicenter, Single-arm, Open-label Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Patients With Influenza and Transmission of Influenza to Household Contacts

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,100

Planned (sponsor's estimate)

Start

Nov 22, 2023

Primary completion

May 11, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 weeks, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study consists of two parts: Part A Surveillance and Part B Transmission. The main purpose of Part A is to evaluate the prevalence of pre-dose and treatment-emergent amino acid substitutions in pediatric participants' \<12 years with influenza treated with baloxavir marboxil. Part B will include a subset of Part A participants who have household contacts (HHCs) recruited to the study. Part B will evaluate the incidence of onward influenza transmission from pediatric index participants (IPs) under 5 years of age and those aged 5 to under 12 years, treated with baloxavir marboxil, to their HHCs. Participants will no longer be enrolled to Part B Transmission as per protocol version 3.

Conditions

  • Influenza

Interventions

  • Baloxavir MarboxilDrug

    Baloxavir marboxil will be administered as an oral suspension per body weight (≥80 kilograms \[kg\]: 80 milligrams \[mg\]; ≥20 kg to \< 80 kg: 40 mg; \<20 kg: 2 milligrams per kilogram \[mg/kg\]).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Percentage of Participants With Resistance-associated Pre-treatment SubstitutionsTime frame: Day 1 (At Baseline)
  2. Part A: Percentage of Participants With Resistance-associated Treatment-emergent SubstitutionsTime frame: Days 4, 6 and 10

Locations

52 sites in 4 countries. Site status is shown where the registry gives one.

  • Central Alabama Research

    Birmingham, Alabama · Recruiting

  • Harrisburg Family Medical Center

    Harrisburg, Arkansas · Recruiting

  • Kendall South Medical Center Inc.

    Miami, Florida · Recruiting

  • Avanza Medical Research Center

    Pensacola, Florida · Withdrawn

  • Tekton Research - Chamblee Georgia

    Chamblee, Georgia · Withdrawn

  • Tekton Research Lawrenceville

    Lawrenceville, Georgia · Withdrawn

  • Velocity Clinical Research at Primary Pediatrics Macon

    Macon, Georgia · Completed

  • Clinical Research Prime

    Idaho Falls, Idaho · Recruiting

  • Mishawaka Osteopathic Clinic

    Mishawaka, Indiana · Recruiting

  • Kentucky Pediatric Research Center

    Bardstown, Kentucky · Recruiting

  • Velocity Clinical Research Lafayette

    Lafayette, Louisiana · Recruiting

  • Velocity Clinical Research, Slidell

    Slidell, Louisiana · Completed

  • Velocity Clinical Research, Grand Island

    Grand Island, Nebraska · Completed

  • Machuca Family Medicine

    Las Vegas, Nevada · Completed

  • Ohio Pediatric Research Association

    Dayton, Ohio · Completed

  • Helios Clinical Research, Inc (former Ventavia Research Group)

    Middleburg Heights, Ohio · Recruiting

  • Frontier Clinical Research

    Smithfield, Pennsylvania · Recruiting

  • Coastal Pediatric Research

    Charleston, South Carolina · Completed

  • Tekton Research - Beaumont

    Beaumont, Texas · Completed

  • Oak Cliff Research Company, LLC

    Dallas, Texas · Active not recruiting

  • Mercury Clinical Research

    Houston, Texas · Completed

  • Pioneer Research Solutions

    Houston, Texas · Recruiting

  • Oak Cliff Research Company, LLC

    Richardson, Texas · Completed

  • Sun Research Institute

    San Antonio, Texas · Withdrawn

  • Tekton Research

    San Antonio, Texas · Completed

  • Siena Research Network

    Sugar Land, Texas · Recruiting

  • Velocity Clinical Research, Salt Lake City

    West Jordan, Utah · Withdrawn

  • Frontier Clinical Research, LLC

    Kingwood, West Virginia · Active not recruiting

  • "Medical Center - Bileva" Ltd

    Blagoevgrad, Bulgaria · Recruiting

  • Medical Centre "Asklepii", OOD

    Dupnitsa, Bulgaria · Completed

  • MHAT " St. Ivan Rilski " Kozloduy

    Kozloduy, Bulgaria · Completed

  • MHAT Stamen Iliev AD

    Montana, Bulgaria · Active not recruiting

  • MHAT City Clinic - Saint George

    Montana, Bulgaria · Completed

  • SHATPPD Dr. Dimitar Gramatikov, Ruse Ltd.

    Rousse, Bulgaria · Completed

  • MHAT Sliven - Military Medial Academy

    Sliven, Bulgaria · Completed

  • AGPSMP Pediatric diseases South park OOD

    Sofia, Bulgaria · Recruiting

  • Medical Center Hera Sofia

    Sofia, Bulgaria · Completed

  • IN VIVO Sp. z o.o.

    Bydgoszcz, Poland · Recruiting

  • NZOZ Vitamed

    Bydgoszcz, Poland · Recruiting

  • Centrum Medyczne Pratia Częstochowa

    Częstochowa, Poland · Recruiting

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.